Distribution · Latin America · Announced 12 Nov 2026

Santhera Pharmaceuticals → SteinCares

Santhera gave SteinCares exclusive distribution rights to AGAMREE (vamorolone) for Duchenne muscular dystrophy in 31 Latin American and Caribbean countries, starting in Brazil; Santhera earns a percentage of net sales.

Parties: Santhera Pharmaceuticals (Switzerland) → SteinCares (Costa Rica)

Deal type
Distribution
Value
Undisclosed
Territory
31 countries in Latin America and the Caribbean, starting with Brazil (Colombia and Argentina also named)
Therapeutic area
Rare / Orphan
Asset
AGAMREE (vamorolone)
Announced
12 Nov 2026

Our analysis

Why this matters

Swiss rare-disease company Santhera Pharmaceuticals announced on 12 November 2026 an exclusive distribution agreement with SteinCares for AGAMREE (vamorolone) across 31 countries in Latin America and the Caribbean. AGAMREE is a dissociative corticosteroid approved for Duchenne muscular dystrophy (DMD) in the US, EU, UK, Switzerland, China, Hong Kong and Canada. Santhera cites about 15,000 people living with DMD in the region, based on global prevalence estimates.

Launch starts in Brazil. SteinCares will file with ANVISA and, in the meantime, supply patients through Brazil's exceptional importation pathways, then roll out across further markets in phases. No filing or launch dates were given.

The full analysis is free to read with a work email on this page.

Source: Santhera press release

Latest deals

All Latin America deals → · All distribution deals → · Browse all emerging-market pharma deals →